

**CORRIGENDUM**

doi:10.1038/nature15720

## **Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment**

E. M. Alexandrova, A. R. Yallowitz, D. Li, S. Xu, R. Schulz, D. A. Proia, G. Lozano, M. Dobbelstein & U. M. Moll

*Nature* **523**, 352–356 (2015); doi:10.1038/nature14430

In this Letter on page 353, the words ‘substrate Hsp90’ should have been included in this sentence as follows: “Likewise, histone deacetylase inhibitors, including FDA-approved SAHA, are promising anti-cancer drugs whose actions involve hyperacetylation of histone and select non-histone targets including HDAC6 substrate Hsp90, thus indirectly inhibiting Hsp90 (ref. 21)”. This has been corrected in the online versions.